Tin tức & Cập nhật
Xem bài viết Ung thư
Xem

Lazertinib improves PFS vs gefitinib in 1L treatment of EGFR-mutated NSCLC
The third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib significantly improves progression-free survival (PFS) vs gefitinib in first-line (1L) treatment of patients with EGFR -mutated, locally advanced or metastatic non-small-cell lung cancer (NSCLC) harbouring an exon 19 deletion or exon 21 L858R mutation, results of the phase III LASER301 trial have shown.

Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
Adding dalpiciclib to an aromatase inhibitor (AI) significantly improves progression-free survival (PFS) vs an AI alone in first-line (1L) treatment of hormone receptor (HR)–positive, HER2-negative advanced breast cancer regardless of patients’ menopausal status, a phase III trial in 42 hospitals in China has shown.

Breast cancer deaths highest within 5 years from diagnosis, decrease afterwards
The risk of mortality for women with early invasive breast cancer is highest during the 5 years after diagnosis, according to a study. Deaths from breast cancer will continue beyond this point, but such risk tends to decrease during each subsequent 5-year period.





